Treatment with a pure factor IX concentrate in a patient with moderate hemophilia B undergoing bilateral total hip replacement.
Recently, a pure factor IX concentrate, licensed in Sweden as Immunine, was prepared through ion exchange and hydrophobic chromotography. Virus inactivation included two steps of steam treatment. Reconstituted Immunine could be kept at room temperature for at least 7 days without any substantial loss of activity. A patient with moderate hemophilia B undergoing bilateral total hip replacement was continuously infused with Immunine by use of a pump. There were no bleeding complications or signs of thrombosis, and the operation markedly improved the patient's range of motion and quality of life.
Tengborn
L
L
Department of Medicine, Sahlgren's Hospital, Göteborg, Sweden.
Stigendal
L
L
Gustafsson
G
G
Strömberg
C
C
Hultmark
P
P
D000990:Antithrombin III / Q000032:analysis; D005164:Factor IX / Q000008:administration & dosage / Q000627:therapeutic use*; D005340:Fibrinogen / Q000032:analysis; D002836:Hemophilia B / Q000097:blood / Q000150:complications* / Q000628:therapy*; D006622:Hip Prosthesis; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010976:Platelet Count
D000990:Antithrombin III; D005164:Factor IX; D005340:Fibrinogen